E-viri
PDF
Recenzirano
Odprti dostop
-
Witztum, Joseph L; Gaudet, Daniel; Freedman, Steven D; Alexander, Veronica J; Digenio, Andres; Williams, Karren R; Yang, Qingqing; Hughes, Steven G; Geary, Richard S; Arca, Marcello; Stroes, Erik S.G; Bergeron, Jean; Soran, Handrean; Civeira, Fernando; Hemphill, Linda; Tsimikas, Sotirios; Blom, Dirk J; O’Dea, Louis; Bruckert, Eric
The New England journal of medicine, 08/2019, Letnik: 381, Številka: 6Journal Article
This phase 3 trial showed that treatment with volanesorsen, an antisense oligonucleotide drug complementary to mRNA encoding apolipoprotein C-III, resulted in a mean reduction in triglyceride levels of 77% over the course of 3 months.
